More Videos
SPECIAL REPORT
MOST SHARED
- The 'Real' Jobless Rate: 17.5% Of Workers Are Unemployed
- GM's Agreement to Sell Saab To Swedish Firm Falls Apart
- US Home Prices Up 5th Month, 2nd Straight Quarter
- FDIC Fund Falls into The Red, Bair Urges Lending
- Buyers Look For Bargains At Luxury Condo Auction
- Weak Dollar Is Golden for Mining Companies
- Revised GDP Reading Puts Growth at 2.8%; Inflation Tame
- Behind The Scenes With Warren Buffett
- Gold Will Collapse Like Oil Did in 2008: Charts
- CA "More Profitable" After Saving Energy: CEO
- On Twitter, Beware False Prophets
- My 2010 Home Price Outlook: UBS Analyst
- Why Are Options Piling into Dollar Tree?
- Novartis 'Cells' Its Flu Vaccine Technology
- Silicon Valley and Hollywood Now Fast Friends
- Markets Can Rise 5-10% in the Near-Term: Strategist
- Busch: The Debt-Interest Rate Paradox
- The Lloyd's Prayer, Leggo My Eggo, Plate Hate & Your Emails
- Buy These 'Competitively Positioned' Stocks: Portfolio Manager
- Turkey Day 101: How Well Do You Know Your Bird?
- Fed Sanguine About US Recovery, Worried on Jobs
- GM's Agreement to Sell Saab Unit Falls Apart
- Consumer Confidence Improves but Still Shaky
- US Home Prices Up 5th Month, 2nd Straight Quarter
- FDIC Fund Falls into The Red, Bair Urges Lending
- Holiday Guide to This Season's Smartphones
- Six Ways to Boost Your Income in a Big Way
- Buyers Look for Bargains at Luxury Condo Auction
PHARMA'S MARKET VIDEO
The New Formula for Faster Vaccines 
1 hr agoNovartis Opens 1st US Plant for Flu Vaccine 7 hrs ago
Cholesterol Drug Battle: Niaspan vs. Zetia 16 Nov 2009
Cardiologist Grades Cholesterol Drug Study 16 Nov 2009
Merck's Cholesterol Drugs Under Pressure 16 Nov 2009
Cholesterol Drug Battle: Merck vs. Abbott Labs 16 Nov 2009
RSS FEED
Pharma's Market
Text Size 
While no one was looking shares of Amgen [AMGN
Loading...
()
] , the world's biggest biotech company (by sales, not market cap--Genentech [DNA
Loading...
()
] is #1 there) have fallen from nearly $76 on January 22nd to the low-60s. What happened? In a nutshell, the company has been buffeted by safety, reimbursement and competitive concerns about its biggest drug franchise known as the acronym EPO. Aranesp and Epogen for the anemia side-effects of kidney dialysis and cancer chemotherapy are multi-billion dollar sellers accounting for nearly half of Amgen's revenue and Credit Suisse analyst Michael Aberman estimates they could make up more than half of the company's bottom line.
There are issues about hemoglobin levels in the kidney patients and recent reports indicate the potential for a higher risk of death among cancer patients. Last week the FDA scheduled an Advisory Committee meeting in May to address it. Amgen says patient safety is its top priority and that the risk/benefit profile of the drugs which have been used on millions of patients is well-established. Nonetheless, the stock has plummeted.
And today, Deutsche Bank analyst Jenn Chao says enough is enough. In the title of a research note to clients and on a subsequent conference call she said, "Stop the 'Chicken Little': Recent Amgen Sell-Off Unwarranted". Deutsche Bank owns at least one percent of AMGN shares and makes a market in the stock. On the call Chao said, "We think it's time to potentially consider (buying) Amgen (stock) at these levels. The pendulum has swung too far to the left. At 12-times 2008 earnings it makes sense to start considering the stock." But she's also the first biotech analyst that I know of to say the shares may have also fallen to the point where they could have become cheap enough for a cash-rich big pharma to buy them up. On the call Chao said, "Amgen starts to look sweeter...and increasingly more savory in the eyes of big pharma. With an Amgen acquisition you're gonna be growing two or three times better and buying into biotech innovation."
Interestingly, Barbara Ryan, Chao's Deutsche Bank colleague who covers big pharma, threw out Amgen late last year in an interview I did with her as a possible target for a company like Pfizer. Leaders of the world's biggest drug company have repeatedly said they're looking at deals of all sizes and that they're interested in becoming a bigger player in biotech. But this would be a HUGE deal. On the call Chao said, "Fair valuation for Amgen on a takeout deserves a 30% to 40% premium off of $90 a share."
Questions? Comments?
Data is a real-time snapshot *Data is delayed at least 15 minutes